Analyzing the potential effects of somatic alterations on survival of gallbladder cancer patients, we observed a trend among patients with wild type TP53 to survive longer than patients with TP53 mutations, which is known to predict failure of chemotherapy in several cancer types50 and is consistent with previous reports observed in gallbladder cancer.51 This evidence concerns the gene TP53 and cancer.